vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Core Viewpoint - vTv Therapeutics Inc. has received a Notice of Allowance from the USPTO for a patent application related to cadisegliatin, which strengthens the protection of this potential first-in-class oral adjunctive therapy for type 1 diabetes [1][2] Company Overview - vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates for diabetes and other chronic diseases [4] - The company's lead asset, cadisegliatin, is currently in a Phase 3 trial and has been granted Breakthrough Therapy designation by the FDA [2][4] Product Details - Cadisegliatin (TTP399) is a liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes [2] - In non-clinical studies, cadisegliatin has shown the ability to increase glucokinase activity independently from insulin, which may improve glycemic control [2] Patent Information - The patent term for the compositions of matter related to cadisegliatin runs through 2041, providing long-term protection for the innovation [1][2]